6 min read
Milestone Monday: Paying Up For The Sure Thing
Across big pharma's late-stage buyouts since 2021, consensus values put the acquired asset below the purchase price in nearly two-thirds of cases, and only 12 of 33 cleared 1.0x. The ones that paid best were rare, specialty and bought cheap, and the certainty was never the part sold at a discount.
